HomeCoronary diseaseAcute coronary syndromes

Acute coronary syndromes

How is the Pandemic Affecting MI? The Chinese Experience

ST elevation acute myocardial infarction has high mortality and morbidity rates. It is normally treated with primary...

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy...

ST-Segment Elevation Myocardial Infarction in the Time of COVID-19

This study cites the experience of 6 sites during the first month of the COVID-19 pandemic in New York....

Reperfusion in the Time of COVID-19. What Has Changed?

We are living a pandemic due to the new COVID-19, but the world was already in the...

MR vs. FFR in Non-Culprit Lesions

Magnetic resonance (MR) and fractional flow reserve (FFR) correlate moderately as regards the assessment of non-culprit lesions...

Virtual ACC 2020 | TICO: Ticagrelor Monotherapy in Acute Coronary Syndromes

Switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduces major bleeding without paying a price...

Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness

Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to...

16 Years of Superiority of Primary Angioplasty

The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial showed the 30-day superiority of patient transport to a...